Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
FoRT 05-BEAT
2024-517200-10-00Phase 2Authorised
- Sponsor
- Fondazione Ricerca Traslazionale
- Start
- Nov 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, randomised trial in non-small cell lung cancer (NSCLC) comparing Atezolizumab with Atezolizumab + bevacizumab (2 arms). Primary endpoint: Overall survival. Planned start Nov 2024; status: authorised.
02
Drugs
atezolizumabbevacizumab
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2024-517200-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-517200-10-00.